Company: LENZ
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001193125-25-100630
Chunk: 41

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 41
---
 Base Salary -24-

See the footnotes to the Summary Compensation Table for the Fiscal Year Ended December 31, 2024 above for information on the base salaries of our named executive officers in effect during fiscal years ended 2024 and 2023. 2024 Annual Cash Bonuses Each of our named executive officers is eligible to participate in an annual cash incentive compensation program which provides participants with an opportunity to earn variable cash incentive compensation based on individual and company performance. For 2024, Mr. Schimmelpennink’s target bonus was 55% of his base salary, and Dr. Odrich’s and Mr. Chevallard’s target bonus was 40% of each of his base salary. The determination of the 2024 bonus amount was discretionary based on our board of directors assessment of company performance against corporate goals. The actual annual cash bonuses awarded to each named executive officer for 2024 performance are set forth above in the “Bonus” column of the Summary Compensation Table for the Fiscal Year Ended December 31, 2024. Outstanding Equity Awards at Fiscal Year-EndDecember 31, 2024 The following table sets forth certain information regarding equity awards granted to our named executive officers that remained outstanding as of December 31, 2024. The number of shares subject to each award and, where applicable, the exercise price per share, reflect all changes as a result of our capitalization adjustments in connection with the Merger.

|                       |     | Option Awards |            |    |     |             |         |     |               |         |    |     |          |       |     |            |            |     | Stock Awards    |       |     |     |                 |         |    |
| Name                  |     | Grant Date    |            |    |     | Number of   
 securities  
 underlying  
 unexercised 
 options (#) 
 exercisable |         |     | Number of     
 securities    
 underlying    
 unexercised   
 options (#)   
 unexercisable |         |    |     | Option   
 exercise 
 price    
 ($)(1)   |       |     | Option     
 expiration 
 date       |            |     | Number of       
 shares or units 
 of stock that   
 have not vested 
 (#)             |       |     |     | Market value of 
 shares or units 
 of stock that   
 have not vested |         |    |
| Evert Schimmelpennink |     |               | 3/8/2021